Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boulder, CO, US. The stock last traded at $58.88, up 0.17% on the session, giving a market capitalisation of $4.21B. On trailing twelve-month figures it carries a trailing P/E of -35.90, a net margin of 0.0%. Its beta of 0.24 implies it has historically moved less than the broad market.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Enliven Therapeutics, Inc. is most often compared with the following Healthcare names: